Camille Chakiba
Camille Chakiba is an expert in Oncology at Institut Bergonié (France). Camille Chakiba has authored 66 publications, the most recent in 2025, and is an investigator in 13 clinical trials, 2 of them ongoing. SLR score: 279 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Genetics - Public Health - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2025
Number : 66
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature. PMID 40266820 — radiotherapy, carcinoma, adenoid cystic, breast neoplasms, neoplasms, radiotherapy, adjuvant, breast, therapeutics, adenoids | Am J Clin Oncol | 2025 | 0 |
| Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer. PMID 40623476 — circulating tumor dna, breast neoplasms, neoplasms, survival analysis, hormones, breast, therapeutics, dna, mutation | Ann Oncol Top journal | 2025 | 0 |
| Cognitive remediation in breast cancer survivors: A study protocol. PMID 39987961 — quality of life, cancer survivors, cognitive remediation, breast neoplasms, neoplasms, cognitive dysfunction, breast, cognition disorders, work, research, therapeutics, memory, cognition, memory, episodic | Contemp Clin Trials | 2025 | 0 |
| Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. PMID 38301187 — epidermal growth factor, growth, breast neoplasms, neoplasms, signs and symptoms, fatigue, receptors, growth factor, breast, patient reported outcome measures, therapeutics, medical oncology, mutation | J Clin Oncol Top journal | 2024 | 5 |
| Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. PMID 38112922 — therapeutics, breast neoplasms, safety, disease-free survival, cyclin-dependent kinases, cyclins, cyclin-dependent kinase 4, progression-free survival, chemotherapy | Breast Cancer Res Treat | 2023 | 9 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine Versus Tucatinib in Combination with Trastuzumab and Capecitabine in People with Locally Advanced or Metastatic Breast Cancer that is HER2 Positive 2025-524498-17-00 — blood-brain barrier, epidermal growth factor, growth, safety, blood, breast neoplasms, brain, neoplasms, central nervous system, neoplasm metastasis, receptors, growth factor, breast, nervous system, capecitabine, trastuzumab | Phase 2/Phase 3 | Not yet recruiting | 2026 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) NCT04551495 — breast neoplasms, neoplasms, letrozole, biopsy, cadherins, breast, research, goserelin, therapeutics, carcinoma, lobular, carcinoma, women | Phase 2 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map